| 崙棫堛栻昳怘昳塹惗尋媶強 |
National Institute of Health Sciences |
| 惗暔栻昳晹 |
Division of Biological Chemistry and Biologicals |
|
丂丂丂 |
亂rINN亃fezakinumab (List 63, 2010, Vol.24, No. 1, p54)
亂pINN亃fezakinumab (List 101, 2009, Vol.23, No. 2, p144)
亂夝愢乮榓栿乯亃
IgG1兩, 峈僸僩僀儞僞乕儘僀僉儞22 (IL22, IL-22, ILTIF, IL-TIF), 僸僩儌僲僋儘乕僫儖峈懱; 柶塽挷惍嵻丏
H嵔 (兞1嵔丆1-450)丗[Homo sapiens VH (IGHV1-2*02 (91.80%) -(IGHD)-IGHJ2*01)
[8.8.14] (1-121) -IGHG1*03 CH1 R120>K, CH3 K130>del (122-450)]丏
L嵔(兩嵔丆1'-217')丗[Homo sapiens V-LAMBDA (IGLV1-40*01 (96.00%) -IGLJ2*01 K123>Q)
[9.3.11] (1'-111') -IGLC2*01 (112'-217')]丏
僕僗儖僼傿僪寢崌偺埵抲丗224-216', 230-230''丆233-233''
摐嵔晅壛埵抲丗301, 301''
亂暘巕幃亃C6408H9886N1710O2016S44
亂CAS斣崋亃1007106-86-6
亂JAN亃枹廂嵹
|
|
| Copyright (C) 丂丂丂Division of Biological Chemistry and Biologicals丂丂丂All
rights reserved. |
|
|